China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ) Latest Company News

Oct 30, 2026, 04:24 UTC
China’s National Medical Products Administration approved China Resources Sanjiu Pharmaceutical’s polyethylene glycol 3350 electrolyte oral solution, deeming it to have passed the generic-drug quality and efficacy consistency evaluation.
Source:
- aastocks.com
- aastocks.com
Oct 23, 2026, 10:33 UTC
China Resources Sanjiu reported revenue of 21.41 billion yuan and net profit attributable to shareholders of 2.158 billion yuan for the first nine months of 2026.
Source:
- finance.sina.cn
Oct 23, 2026, 10:33 UTC
China Resources Sanjiu reported third-quarter 2026 revenue of 6.396 billion yuan, down 10.87% year over year, and net profit attributable to shareholders of 487 million yuan, down 9.43%.
Source:
- finance.sina.cn
Oct 22, 2026, 09:40 UTC
China’s National Medical Products Administration approved China Resources Sanjiu’s Yiguanjian granules for marketing.
Source:
- aastocks.com
- aastocks.com
Oct 8, 2026, 11:29 UTC
China Resources Sanjiu said shareholders approved a 2026 interim cash dividend of RMB 4.15 per 10 shares, totaling RMB 691 million.
Source:
- finance.sina.cn
Sep 11, 2026, 04:16 UTC
China Resources Pharmaceutical's subsidiary China Resources Sanjiu received approval from the National Medical Products Administration to launch mupirocin ointment in mainland China.
Source:
- aastocks.com
Sep 4, 2026, 13:59 UTC
China Resources Sanjiu held an investor research meeting on September 4, 2026, in connection with its 2026 interim results briefing, attended by its chairman, president, CFO, and other executives.
Source:
- wap.eastmoney.com
Aug 21, 2026, 11:15 UTC
China Resources Sanjiu disclosed its semi-annual report on August 21, reporting net profit attributable to shareholders of 1.671 billion yuan, down 7.96% year-on-year.
Source:
- finance.sina.cn
Aug 21, 2026, 11:15 UTC
China Resources Sanjiu announced a cash dividend of 4.15 yuan per 10 shares (tax included) for all shareholders, with no bonus shares or capital reserve conversion.
Source:
- finance.sina.cn

000999.SZ

China’s National Medical Products Administration approved China Resources Sanjiu Pharmaceutical’s polyethylene glycol 3350 electrolyte oral solution, deeming it to have passed the generic-drug quality and efficacy consistency evaluation.

China Resources Sanjiu reported revenue of 21.41 billion yuan and net profit attributable to shareholders of 2.158 billion yuan for the first nine months of 2026.

China Resources Sanjiu reported third-quarter 2026 revenue of 6.396 billion yuan, down 10.87% year over year, and net profit attributable to shareholders of 487 million yuan, down 9.43%.

China’s National Medical Products Administration approved China Resources Sanjiu’s Yiguanjian granules for marketing.

China Resources Sanjiu said shareholders approved a 2026 interim cash dividend of RMB 4.15 per 10 shares, totaling RMB 691 million.

China Resources Pharmaceutical's subsidiary China Resources Sanjiu received approval from the National Medical Products Administration to launch mupirocin ointment in mainland China.

China Resources Sanjiu held an investor research meeting on September 4, 2026, in connection with its 2026 interim results briefing, attended by its chairman, president, CFO, and other executives.

China Resources Sanjiu disclosed its semi-annual report on August 21, reporting net profit attributable to shareholders of 1.671 billion yuan, down 7.96% year-on-year.

China Resources Sanjiu announced a cash dividend of 4.15 yuan per 10 shares (tax included) for all shareholders, with no bonus shares or capital reserve conversion.